SVB Wealth LLC Invests $5.04 Million in IQVIA Holdings Inc. (NYSE:IQV)

SVB Wealth LLC purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 25,659 shares of the medical research company’s stock, valued at approximately $5,042,000.

Several other institutional investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its stake in shares of IQVIA by 4.9% in the third quarter. Nisa Investment Advisors LLC now owns 11,346 shares of the medical research company’s stock worth $2,689,000 after purchasing an additional 530 shares during the last quarter. US Bancorp DE grew its position in shares of IQVIA by 62.2% in the 3rd quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock worth $6,413,000 after buying an additional 10,379 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of IQVIA by 35.2% during the third quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock valued at $96,000 after buying an additional 106 shares during the period. Chicago Partners Investment Group LLC bought a new position in shares of IQVIA during the third quarter valued at approximately $218,000. Finally, Optas LLC purchased a new stake in IQVIA in the third quarter worth $210,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on IQV shares. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Leerink Partners restated an “outperform” rating and set a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Trading Up 1.3 %

Shares of IQV stock opened at $188.89 on Friday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $184.66 and a 12-month high of $261.73. The stock has a market capitalization of $33.26 billion, a P/E ratio of 25.19, a P/E/G ratio of 1.99 and a beta of 1.48. The firm’s 50 day moving average is $199.13 and its 200 day moving average is $214.80.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.